Pharma Journalist -

Daiichi Sankyo received notification of acceptance by the U.S. Food and Drug Administration (FDA) of the New Drug Application (NDA) of quizartinib in combination with standard…
Read More...

Kite, a Gilead Company and Refuge Biotechnologies, Inc. announced that Kite has entered into an exclusive, worldwide license agreement with Refuge, a synthetic biology company for…
Read More...

ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application (NDA) for neffy for the emergency treatment…
Read More...

Sumitovant Biopharma Ltd. in conjunction with parent company Sumitomo Pharma Co., Ltd. and Myovant Sciences announced today that they have entered into a definitive agreement pursuant…
Read More...

AbbVie announces that the U.S. Food and Drug Administration (FDA) has approved RINVOQ (upadacitinib 15 mg, once daily), an oral therapy, for the treatment of adults with active…
Read More...

HOOKIPA Pharma Inc. a company developing a new class of immunotherapies based on its proprietary arenavirus platform, announced a strategic collaboration and license agreement with…
Read More...

Corium, LLC a commercial-stage biopharmaceutical company leading the development and commercialization of novel neuroscience therapies, and Gurnet Point Capital (“Gurnet Point”), a…
Read More...

Takeda, Zedira and Dr. Falk Pharma GmbH announced a collaboration and licensing agreement to develop ZED1227/TAK-227, a Phase 2b investigational therapy for the treatment of celiac…
Read More...

Amgen announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc., a biopharmaceutical company focused on orally administered therapeutics to…
Read More...

AbbVie announced the acquisition of DJS Antibodies Ltd ("DJS"), a privately-held UK-based biotechnology company dedicated to discovering and developing antibody medicines that target…
Read More...